Pfizer to file tofacitinib for RA by year end
This article was originally published in Scrip
Executive Summary
Pfizer confirmed it is gearing up to file for US and EU approval of its oral JAK inhibitor, tofacitinib, in rheumatoid arthritis by the end of the year as it presented the full results of the pivotal ORAL Sync trial as well as data from another study investigating atorvastatin use in patients taking tofacitinib at the European League Against Rheumatism congress in London.